Trial Profile

A Phase 2 Study randomized, double-blind, two-part (Part A and Part B) Proof-of-Concept clinical study evaluating CYC-126 in Treatment Resistant Depression who are candidates for monitored anesthesia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 03 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Mar 2026 New trial record
17 Feb 2026 According to Cyclerion Therapeutics media release, company received Positive Pre-Investigational New Drug (IND) Written Feedback from the U.S. Food and Drug Administration on CYC-126 Phase 2 POC study in TRD and its path to potential regulatory approval.
17 Feb 2026 According to Cyclerion Therapeutics media release, Company remains on track to initiate the Phase 2 study in the second half of 2026, with the first patient to be enrolled in Australia and U.S. enrollment commencing in the first half of 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com